An interview with Sean Werner, President, Sexton Biotechnologies
We spoke to Sean Werner, President Sexton Biotechnologies about embedding flexibility into automated bioprocessing, especially for early-stage biotechs.
Sean discusses the main advantages of automating as early as possible and how he and his team are supporting biotech through the sometimes-arduous process of integrating new technology into a validated bioprocess.
Here are the questions we asked, watch this six-minute video to hear more…
- For early-stage biotech and start-ups that want to automate, what are the limiting factors?
- What are the strategic and technical advantages to automating as early as possible for advanced therapy biotechs?
- Revisions to automated manufacturing processes of advanced therapies can be costly and time-consuming and pose regulatory challenges. How are you working to help biotech solve this and allow for more flexibility in the manufacturing process?
- What would you say are the next big automation-related challenges that technology innovators should be focused on solving?